Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy

Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy

Atezolizumab/bevacizumab (Atezo/Bev) combination therapy has become a front-line therapy for advanced hepatocellular carcinoma (HCC), but approximately 20% of patients are nonresponders. We investigated circulating biomarkers to predict therapeutic outcomes. We performed simultaneous measurement of...

Full description

Bibliographic Details
Main Authors: Yuta Myojin, Takahiro Kodama, Ryotaro Sakamori, Kazuki Maesaka, Takayuki Matsumae, Yoshiyuki Sawai, Yasuharu Imai, Kazuyoshi Ohkawa, Masanori Miyazaki, Satoshi Tanaka, Eiji Mita, Seiichi Tawara, Takayuki Yakushijin, Yasutoshi Nozaki, Hideki Hagiwara, Yuki Tahata, Ryoko Yamada, Hayato Hikita, Tomohide Tatsumi, Tetsuo Takehara
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
multiplex immunoassay
immune checkpoint inhibitor
anti-VEGF antibody
anti-PD-L1 antibody
liver cancer
Online Access:https://www.mdpi.com/2072-6694/14/4/883

Internet

https://www.mdpi.com/2072-6694/14/4/883

Similar Items